These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1114 related articles for article (PubMed ID: 1643424)
21. Combined vaccination with major histocompatibility class I and interleukin 2 gene-transduced melanoma cells synergizes the cure of postsurgical established lung metastases. Porgador A; Tzehoval E; Vadai E; Feldman M; Eisenbach L Cancer Res; 1995 Nov; 55(21):4941-9. PubMed ID: 7585534 [TBL] [Abstract][Full Text] [Related]
22. Independent cell types are involved in the induction of antimelanoma responses in C57BL/6 mice immunized with interleukin-2-secreting allogeneic mouse fibroblasts expressing melanoma-associated antigens. Kim TS; Collins MK; Cohen EP J Immunother Emphasis Tumor Immunol; 1993 Nov; 14(4):298-304. PubMed ID: 7904182 [TBL] [Abstract][Full Text] [Related]
23. Anti-metastatic effect by in vivo administration of concanavalin A through augmentation of T-derived activated killer activity: efficacy to B16 melanoma expressed MHC antigen. Taniguchi K; Kawano YI; Toshitani A; Karashima A; Nomoto K Cell Immunol; 1989 May; 120(2):460-9. PubMed ID: 2785862 [TBL] [Abstract][Full Text] [Related]
24. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation. Xu D; Gu P; Pan PY; Li Q; Sato AI; Chen SH Int J Cancer; 2004 Apr; 109(4):499-506. PubMed ID: 14991570 [TBL] [Abstract][Full Text] [Related]
25. Identification of melanoma cell surface antigens immunogenic in mice. Johnston D; el Rouby S; Bystryn JC Cancer Biother; 1994; 9(1):29-38. PubMed ID: 7812355 [TBL] [Abstract][Full Text] [Related]
26. Intrasplenic vaccination against experimental melanoma. Shrayer D; Park C; Kouttab N; Bogaars H; McInnis R; Paul S; Maizel A; Hearing V; Wanebo H Int J Oncol; 1996 Jul; 9(1):123-9. PubMed ID: 21541491 [TBL] [Abstract][Full Text] [Related]
27. Immunostimulatory neem leaf preparation acts as an adjuvant to enhance the efficacy of poorly immunogenic B16 melanoma surface antigen vaccine. Baral R; Mandal I; Chattopadhyay U Int Immunopharmacol; 2005 Jul; 5(7-8):1343-52. PubMed ID: 15914339 [TBL] [Abstract][Full Text] [Related]
28. Efficacy of tumor cell vaccine after incorporating monophosphoryl lipid A (MPL) in tumor cell membranes containing tumor-associated ganglioside. Ravindranath MH; Brazeau SM; Morton DL Experientia; 1994 Jul; 50(7):648-53. PubMed ID: 8033972 [TBL] [Abstract][Full Text] [Related]
29. Recombinant vaccinia virus vaccine against the human melanoma antigen p97 for use in immunotherapy. Estin CD; Stevenson US; Plowman GD; Hu SL; Sridhar P; Hellström I; Brown JP; Hellström KE Proc Natl Acad Sci U S A; 1988 Feb; 85(4):1052-6. PubMed ID: 3422478 [TBL] [Abstract][Full Text] [Related]
30. The intracellular association of B700 and B50 murine melanoma antigens and their role in tumor rejection. Gersten DM; Williams LJ; Moody D; Montague PM; Law LW; Hearing VJ Int J Cancer; 1989 Mar; 43(3):497-500. PubMed ID: 2925280 [TBL] [Abstract][Full Text] [Related]
32. Tumours can act as adjuvants for humoral immunity. Brown DM; Fisher TL; Wei C; Frelinger JG; Lord EM Immunology; 2001 Apr; 102(4):486-97. PubMed ID: 11328383 [TBL] [Abstract][Full Text] [Related]
33. Multiple antigens related to the major envelope glycoprotein of murine leukemia virus expressed on B16 melanoma cells as targets of host immune response. Stackpole CW; Demsey A Invasion Metastasis; 1984; 4(1):28-46. PubMed ID: 6329988 [TBL] [Abstract][Full Text] [Related]
34. Recombinant CD63/ME491/neuroglandular/NKI/C-3 antigen inhibits growth of established tumors in transgenic mice. Li J; Li W; Liang S; Cai D; Kieny MP; Jacob L; Linnenbach A; Abramczuk JW; Bender H; Sproesser K; Swoboda R; Somasundaram R; Guerry D; Herlyn D J Immunol; 2003 Sep; 171(6):2922-9. PubMed ID: 12960315 [TBL] [Abstract][Full Text] [Related]
35. Vaccination with B16 melanoma cells expressing a secreted form of interleukin-1beta induces tumor growth inhibition and an enhanced immunity against the wild-type B16 tumor. Björkdahl O; Dohlsten M; Sjögren HO Cancer Gene Ther; 2000 Oct; 7(10):1365-74. PubMed ID: 11059695 [TBL] [Abstract][Full Text] [Related]
36. Anti-tumor effect of splenocytes treated with RNA from animals immunized with bovine myelin basic protein. Watanabe MA; De Lucca FL Cell Mol Biol (Noisy-le-grand); 1996 Mar; 42(2):249-54. PubMed ID: 8696262 [TBL] [Abstract][Full Text] [Related]
37. Effect of immunization with anti-idiotypic antibody to melanoma antigen on lung metastasis in mice. Minamizuka T; Eto H; Nakata M; Yagita H; Okumura K Nihon Geka Hokan; 1992 Nov; 61(6):413-22. PubMed ID: 1306979 [TBL] [Abstract][Full Text] [Related]
38. Multiple pathways to tumor immunity and concomitant autoimmunity. Turk MJ; Wolchok JD; Guevara-Patino JA; Goldberg SM; Houghton AN Immunol Rev; 2002 Oct; 188():122-35. PubMed ID: 12445286 [TBL] [Abstract][Full Text] [Related]
39. Adenovirus-mediated expression of interleukin-12 induces natural killer cell activity and complements adenovirus-directed gp75 treatment of melanoma lung metastases. Hirschowitz EA; Crystal RG Am J Respir Cell Mol Biol; 1999 May; 20(5):935-41. PubMed ID: 10226063 [TBL] [Abstract][Full Text] [Related]
40. Association between induction of anti high molecular weight-melanoma associated antigen (HMW-MAA) immunity with mouse antiidiotypic monoclonal antibody (MoAb) MK2-23 and prolongation of survival in patients with melanoma. Chen ZJ; Yang H; Liu CC; Mittelman A; Ferrone S Pigment Cell Res; 1992; Suppl 2():113-22. PubMed ID: 1409413 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]